Eur Rev Med Pharmacol Sci 2019; 23 (10): 4143-4148
DOI: 10.26355/eurrev_201905_17916

Long non-coding RNA DSCAM-AS1 indicates a poor prognosis and modulates cell proliferation, migration and invasion in ovarian cancer via upregulating SOX4

Y. Li, J. Hao, Y.-M. Jiang, Y. Liu, S.-H. Zhang

Department of Gynecology, Weihai Municipal Hospital, Weihai, China. jljack@126.com


OBJECTIVE: Recent studies have revealed that long noncoding RNAs (lncRNAs) play a crucial role in tumor progression. Ovarian cancer is a common type of fatal gynecological cancer worldwide. This study aims to investigate how lncRNADSCAM-AS1 functions in the progression of ovarian cancer.
PATIENTS AND METHODS: DSCAM-AS1 expression of both ovarian cancer cells and 56 paired of tissue samples was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Moreover, the function of DSCAM-AS1 was identified via transwell assay, wound healing assay, colony formation assay and proliferation assay in vitro. The underlying mechanism was explored through qRT-PCR and Western blot assay.
RESULTS: DSCAM-AS1 expression was remarkably upregulated in tumor tissues compared with that in the adjacent normal tissues. Besides, ovarian cancer proliferation, migration and invasion were promoted after overexpression of DSCAM-AS1 in vitro. Moreover, after overexpression of DSCAM-AS1, SOX4 was upregulated at mRNA and protein level in vitro. Furthermore, the expression of SOX4 in tumor tissues was positively correlated with the expression of DSCAM-AS1.
CONCLUSIONS: The above results suggested that DSCAM-AS1 can promote cell migration, invasion and proliferation in ovarian cancer by upregulating SOX4, which may offer a new therapeutic intervention for patients with ovarian cancer.

This article has been withdrawn. The Publisher apologizes for any inconvenience this may cause.
Free PDF Download

To cite this article

Y. Li, J. Hao, Y.-M. Jiang, Y. Liu, S.-H. Zhang
Long non-coding RNA DSCAM-AS1 indicates a poor prognosis and modulates cell proliferation, migration and invasion in ovarian cancer via upregulating SOX4

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 10
Pages: 4143-4148
DOI: 10.26355/eurrev_201905_17916